CR6261

BIOLOGICAL3 trials

Sponsors

Crucell Holland BV, Janssen Pharmaceutical K.K., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

H1N1 Influenza Healthy VolunteersHealthyInfluenza

Phase 1

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants

WithdrawnNCT02016066

Janssen Pharmaceutical K.K.Healthy

Start: 2013-12-31End: 2014-04-30Updated: 2017-02-06

Phase 2

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

WithdrawnNCT01992276

Crucell Holland BVInfluenza

Start: 2013-12-31End: 2015-02-28Updated: 2014-03-04

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

CompletedNCT02371668

National Institute of Allergy and Infectious Diseases (NIAID)H1N1 Influenza Healthy Volunteers

Start: 2015-02-25End: 2018-11-30Updated: 2020-03-17

Related Papers

Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model

Clinical Infectious Diseases2020-11-1148 citations